Market Recovery Expectations

Bayer currently faces multiple challenges including litigation, patent expirations, and new drug development, but it is outlining a sales recovery scenario targeting 2026. It is analyzing the possibility that declining sales of existing products will be offset by innovative therapies and FDA approvals. This optimism stems from an increasing number of high‑value pipeline candidates, which has focused investor attention.

Impact of Litigation and Patent Expirations

Ongoing patent lawsuits and upcoming patent expirations are short‑term sales pressure factors. A patent cliff refers to the rapid loss of sales when exclusivity for core products ends, directly affecting the company’s financial structure. However, Bayer is preparing strategies to secure royalty income depending on litigation outcomes or to launch substitute products quickly.

New Drug Development and FDA Approval Outlook

Bayer holds several innovative therapeutic candidates in its pipeline, particularly in oncology and cardiovascular areas, and is targeting FDA approval. FDA approval signifies entry into the U.S. market and is a key driver for substantial sales expansion. Achieving these approvals is expected to contribute not only to sales recovery but also to an improved corporate image.

Implications for Investors and the Industry

Bayer’s recovery strategy goes beyond sales growth to include risk management and pipeline diversification. The industry views how large pharma companies overcome patent expirations and litigation risks as a major factor shaping future competitive dynamics. Consequently, investors should monitor Bayer’s clinical progress and regulatory timelines.